Transplantation Proceedings
Volume 40, Issue 6 , Pages 1833-1838 , July 2008

Hyperimmunized Patients Awaiting Cadaveric Kidney Graft: Is There a Quick Desensitization Possible?

  • A. Faenza

      Affiliations

    • Department of Kidney Transplant Surgery, S. Orsola University Hospital, Bologna, Italy
    • Corresponding Author InformationAddress reprint requests to Prof Alessandro Faenza, Dipartimento di Chirurgia, Ospedale S. Orsola, Via Massarenti 9, 40122 Bologna, Italy.
    • ,
  • G. Fuga

      Affiliations

    • Department of Kidney Transplant Surgery, S. Orsola University Hospital, Bologna, Italy
    • ,
  • R. Bertelli

      Affiliations

    • Department of Kidney Transplant Surgery, S. Orsola University Hospital, Bologna, Italy
    • ,
  • M.P. Scolari

      Affiliations

    • Department of Nephrology, Dialysis and Transplantation, S. Orsola University Hospital, Bologna, Italy.
    • ,
  • A. Buscaroli

      Affiliations

    • Department of Nephrology, Dialysis and Transplantation, S. Orsola University Hospital, Bologna, Italy.
    • ,
  • S. Stefoni

      Affiliations

    • Department of Nephrology, Dialysis and Transplantation, S. Orsola University Hospital, Bologna, Italy.

References 

  1. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 Trial. J Am Soc Nephrol. 2004;15:3256
  2. Doxiadis IIN, Duquesnoy RJ, Claas FHJ. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol. 2005;17:536
  3. Mosconi G, Scolari MP, Feliciangeli G, et al. Combined liver–kidney transplantation with preformed anti-HLA antibodies: a case report. Transplant Proc. 2006;38:1125
  4. Fuggle SV, Martin S. Towards performing transplantation in highly sensitized patients. Transplantation. 2004;78:186
  5. Cai J, Terasaki PI. Human leukocyte antigen antibodies for monitoring transplant patients. Surg Today. 2005;35:605
  6. Vasilescu ER, Ho EK, Colovai AI, et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol. 2006;67:597
  7. Crew RJ, Ratner LE. Overcoming immunologic incompatibility: transplanting the difficult to transplant patient. Semin Dialysis. 2005;18:474
  8. Anglicheau D, Loupy A, Suberbielle C, et al. One-year outcome of high-immunological risk patients treated with intravenous immunoglobulins combined with quadritherapy. In: World Transplant Congress, Boston. 2006;(Abstract WTC06L_2159)
  9. Cook DJ, El Fettouh HA, Gjertson DW, et al. Flow cytometry crossmatching (FCXM) in the UNOS Kidney Transplant Registry. Clin Transpl. 1998;413
  10. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant. 2003;3:1488
  11. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725
  12. Piatosa B, Rubik J, Grenda R. Is positive flow cytometric cross-match a risk factor for early cadaveric kidney graft dysfunction?. Transplant Proc. 2006;38:53
  13. Fagundes I, Michelon T, Schoroeder R, et al. Immunoglobulin G-positive in B-cell cross-match decreases kidney allograft survival. Transplant Proc. 2005;37:2753
  14. Michelon T, Schoroeder R, Fagundes I, et al. Clinical relevance of low levels of preformed alloantibodies detected by flow cytometry in the first year post-kidney transplantation. Transplant Proc. 2005;37:2750
  15. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal transplant patients. Transplantation. 2003;76:1519
  16. Montgomery R. Desensitization: highly sensitized (positive crossmatch) program. In: World Transplant Congress, Boston. 2006;(Abstract WTC06L)
  17. Gloor J. Kidney transplantation in the hyperimmunized patient. Contrib Nephrol. 2005;146:11
  18. Vo AA, Toyoda M, Peng A, et al. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IvIg. Am J Transplant. 2006;6:2384
  19. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int. 2004;17:1
  20. Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanism of action. Liver Transpl. 2005;11:1469
  21. Magee CC. Transplantation across previously incompatible immunological barriers. Transpl Int. 2006;19:87
  22. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000;70:1531
  23. Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the Antibody Working Group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation. 2004;78:181
  24. Leventhal JR, Friedewald JJ, Gallon L, et al. Desensitization of living donor renal transplant recipients using rituximab and alemtuzumab induction therapy. In: World Transplant Congress, Boston. 2006;(Abstract WTC06_915)
  25. Opelz G, Susal C. A positive crossmatch and treatment with IvIg. Am J Transplant. 2005;5:2601
  26. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003;3:653
  27. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003;76:631
  28. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet. 1996;348:1208
  29. Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation. 2005;79:696
  30. Braun N, Wernet D, Schnaidt M, et al. Successful treatment of accelerated vascular rejection in highly immunised renal transplant recipient with immunoadsorption and 15-deoxyspergualin. Transpl Int. 2004;17:384
  31. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IvIg desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346
  32. Toki D, Tanabe K, Ishida H, et al: Excellent results of low-dose rituximab induction therapy for highly sensitized kidney transplant recipients. (Abstract WTC06_671)
  33. Vo AA, Lukovsky M, Toyoda M, et al: Efficacy and safety profiles of subcutaneous (SQ) Campath 1H administration in crossmatch (CMX) positive patients desensitized with intravenous gammaglobulin. (Abstract WTC06L_664)
  34. Kraus ES, Lepley D, Segev D, et al: The utility of protocol biopsies in incompatible kidney transplant recipients. (Abstract WTC06L_1194)
  35. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000;70:1531
  36. Thielke J, DeChristopher PJ, Sankary H, et al. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc. 2005;37:643
  37. Scornik JC, Ireland JE, Howard RJ, et al. Assessment of the risk for broad sensitization by blood transfusions. Transplantation. 1984;37:249
  38. Scornik JC, Ireland JE, Salomon DR, et al. Pretransplant blood transfusions in patients with previous pregnancies. Transplantation. 1987;43:449

PII: S0041-1345(08)00735-5

doi: 10.1016/j.transproceed.2008.05.078

Transplantation Proceedings
Volume 40, Issue 6 , Pages 1833-1838 , July 2008

Article Tools